Verapamil - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (16)Enzymes (10)Transporters (13)

Targets (16)Enzymes (10)Transporters (13)Biointeractions (47)

Identification

Name

Verapamil

Accession Number

DB00661 (APRD00335)

Type

Small Molecule

Groups

Approved

Description

A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Calan

Calan sr

Covera-hs

CP-16533-1

CP-165331

D-365

Iproveratril

Isoptin

Isoptin sr

Tarka

Vérapamil

Verapamil

Verapamilo

Verapamilum

Verelan

External IDs

CP 16533-1 / D 365

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Verapamil Hydrochloride	V3888OEY5R	152-11-4	DOQPXTMNIUCOSY-UHFFFAOYNA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Alti-verapamil - 120mg	Tablet	120 mg	Oral	Altimed Pharma Inc.	1990-12-31	2004-08-03	Canada
Alti-verapamil - 80mg	Tablet	80 mg	Oral	Altimed Pharma Inc.	1990-12-31	2004-08-03	Canada
Calan	Tablet, film coated	80 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1984-09-10	Not applicable	US
Calan	Tablet, film coated	120 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1984-09-10	Not applicable	US
Calan SR	Tablet, film coated, extended release	240 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1986-12-16	Not applicable	US
Calan SR	Tablet, film coated, extended release	120 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1991-03-06	Not applicable	US
Calan SR	Tablet, film coated, extended release	180 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1989-12-15	Not applicable	US
Covera-HS	Tablet, extended release	180 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1996-02-26	2016-10-13	US
Covera-HS	Tablet, extended release	180 mg	Oral	Pfizer	1997-11-13	2013-02-15	Canada
Covera-HS	Tablet, extended release	240 mg/1	Oral	G.D. Searle LLC Division of Pfizer Inc	1996-02-26	2016-10-13	US
Covera-HS	Tablet, extended release	240 mg	Oral	Pfizer	1997-11-13	2013-02-15	Canada
Dom-verapamil SR 240mg Tablets	Tablet, extended release	240 mg	Oral	Dominion Pharmacal	1999-12-16	Not applicable	Canada
Isoptin Inj 2.5mg/ml	Liquid	2.5 mg	Intravenous	Abbott	1984-12-31	2007-07-31	Canada
Isoptin SR	Tablet, extended release	180 mg	Oral	Bgp Pharma Ulc	1994-04-21	Not applicable	Canada
Isoptin SR	Tablet, extended release	240 mg	Oral	Bgp Pharma Ulc	1988-12-31	Not applicable	Canada
Isoptin SR	Tablet, extended release	120 mg	Oral	Bgp Pharma Ulc	1991-12-31	Not applicable	Canada
Isoptin Tab 120mg	Tablet	120 mg	Oral	Abbott	1982-12-31	2007-07-31	Canada
Isoptin Tab 80mg	Tablet	80 mg	Oral	Abbott	1982-12-31	2007-07-31	Canada
Med Verapamil Tablets	Tablet	120 mg	Oral	Medican Pharma Incorporated	1999-03-08	2011-03-29	Canada
Med Verapamil Tablets	Tablet	80 mg	Oral	Medican Pharma Incorporated	1999-03-08	2011-03-29	Canada
Mylan-verapamil	Tablet	80 mg	Oral	Mylan Pharmaceuticals	1998-05-25	Not applicable	Canada
Mylan-verapamil	Tablet	120 mg	Oral	Mylan Pharmaceuticals	1998-05-11	Not applicable	Canada
Mylan-verapamil SR	Tablet, extended release	240 mg	Oral	Mylan Pharmaceuticals	1996-12-31	2016-09-01	Canada
Mylan-verapamil SR	Tablet, extended release	240 mg	Oral	Mylan Pharmaceuticals	2016-09-01	Not applicable	Canada
Mylan-verapamil SR	Tablet, extended release	120 mg	Oral	Mylan Pharmaceuticals	Not applicable	Not applicable	Canada
Mylan-verapamil SR	Tablet, extended release	180 mg	Oral	Mylan Pharmaceuticals	2016-06-29	Not applicable	Canada
Mylan-verapamil SR	Tablet, extended release	120 mg	Oral	Mylan Pharmaceuticals	1996-12-31	Not applicable	Canada
Mylan-verapamil SR	Tablet, extended release	180 mg	Oral	Mylan Pharmaceuticals	1996-12-31	2016-06-29	Canada
Novo-veramil	Tablet	120 mg	Oral	Teva	1989-12-31	Not applicable	Canada
Novo-veramil	Tablet	80 mg	Oral	Teva	1989-12-31	Not applicable	Canada
Novo-veramil SR	Tablet, extended release	240 mg	Oral	Teva	1996-12-31	Not applicable	Canada
Nu-verap SR	Tablet, extended release	120 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-verap SR	Tablet, extended release	240 mg	Oral	Nu Pharm Inc	2004-07-19	2012-09-04	Canada
Nu-verap SR	Tablet, extended release	180 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-verap Tab 120mg	Tablet	120 mg	Oral	Nu Pharm Inc	1990-12-31	2012-09-04	Canada
Nu-verap Tab 80mg	Tablet	80 mg	Oral	Nu Pharm Inc	1990-12-31	2012-09-04	Canada
Penta-verapamil - 120mg	Tablet	120 mg	Oral	Pentapharm Ltd.	1997-06-25	2004-07-30	Canada
Penta-verapamil - 80mg	Tablet	80 mg	Oral	Pentapharm Ltd.	1997-06-25	2004-07-30	Canada
PHL-verapamil SR	Tablet, extended release	240 mg	Oral	Pharmel Inc	2002-05-31	Not applicable	Canada
PMS-verapamil SR	Tablet, extended release	240 mg	Oral	Pharmascience Inc	1999-09-01	Not applicable	Canada
Pro-verapamil SR	Tablet, extended release	120 mg	Oral	Pro Doc Limitee	2009-06-15	Not applicable	Canada
Pro-verapamil SR	Tablet, extended release	180 mg	Oral	Pro Doc Limitee	2009-06-15	Not applicable	Canada
Pro-verapamil SR	Tablet, extended release	240 mg	Oral	Pro Doc Limitee	2008-07-09	Not applicable	Canada
Riva-verapamil SR	Tablet, extended release	240 mg	Oral	Laboratoire Riva Inc	2005-09-14	Not applicable	Canada
Taro-verapamil Tab 120mg	Tablet	120 mg	Oral	Taro Pharmaceuticals, Inc.	1993-12-31	2000-08-31	Canada
Taro-verapamil Tab 80mg	Tablet	80 mg	Oral	Taro Pharmaceuticals, Inc.	1993-12-31	2000-08-31	Canada
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	Actavis Pharma Company	1990-05-29	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	bryant ranch prepack	1990-05-29	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	180 mg/1	Oral	Actavis Pharma Company	1990-05-29	Not applicable	US
Verapamil Hydrochloride	Injection	2.5 mg/mL	Intravenous	Exela Pharma Sciences, Llc.	2017-02-01	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	360 mg/1	Oral	Physicians Total Care, Inc.	2009-02-12	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	120 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-07-24	2016-10-13	US
Verapamil Hydrochloride	Injection	2.5 mg/mL	Intravenous	Exela Pharma Sciences, Llc.	2016-04-22	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	200 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	240 mg/1	Oral	Actavis Pharma Company	1990-05-29	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	bryant ranch prepack	1998-11-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	120 mg/1	Oral	Actavis Pharma Company	1990-05-29	Not applicable	US
Verapamil Hydrochloride	Capsule, delayed release pellets	180 mg/1	Oral	Carilion Materials Management	1990-05-29	Not applicable	US
Verapamil Hydrochloride Injection USP	Liquid	2.5 mg	Intravenous	Sandoz Canada Incorporated	1995-12-31	Not applicable	Canada
Verapamil Hydrochloride Injection, USP	Solution	2.5 mg	Intravenous	Hospira, Inc.	1994-12-31	Not applicable	Canada
Verapamil Injection 2.5mg/ml	Liquid	2.5 mg	Intravenous	Novopharm Limited	1994-12-31	2005-08-10	Canada
Verapamil SR	Tablet, extended release	240 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20	Canada
Verapamil Tab 80mg	Tablet	80 mg	Oral	Pro Doc Limitee	1990-12-31	2012-07-23	Canada
Verapamil-120 Tab	Tablet	120 mg	Oral	Pro Doc Limitee	1990-12-31	2009-07-23	Canada
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Physicians Total Care, Inc.	2003-06-12	Not applicable	US
Verelan	Capsule, delayed release pellets	120 mg/1	Oral	Kremers Urban	1990-05-29	Not applicable	US
Verelan	Capsule, extended release	120 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable	Canada
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Kremers Urban	1990-05-29	Not applicable	US
Verelan	Capsule, extended release	180 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable	Canada
Verelan	Capsule, delayed release pellets	120 mg/1	Oral	Ucb Inc	1990-05-29	2016-10-26	US
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Physicians Total Care, Inc.	2004-08-12	Not applicable	US
Verelan	Capsule, delayed release pellets	180 mg/1	Oral	Kremers Urban	1990-05-29	Not applicable	US
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Ucb Inc	1990-05-29	2016-10-26	US
Verelan	Capsule, extended release	240 mg	Oral	Recro Gainesville Llc	1994-12-31	Not applicable	Canada
Verelan	Capsule, delayed release pellets	180 mg/1	Oral	Ucb Inc	1990-05-29	2016-10-26	US
Verelan	Capsule, delayed release pellets	240 mg/1	Oral	Kremers Urban	1990-05-29	Not applicable	US
Verelan	Capsule, delayed release pellets	360 mg/1	Oral	Ucb Inc	1990-05-29	2016-10-26	US
Verelan PM	Capsule, extended release	300 mg/1	Oral	Ucb Inc	1998-11-25	2016-10-26	US
Verelan PM	Capsule, extended release	300 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verelan PM	Capsule, extended release	100 mg/1	Oral	Ucb Inc	1998-11-25	2016-10-26	US
Verelan PM	Capsule, extended release	100 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verelan PM	Capsule, extended release	200 mg/1	Oral	Ucb Inc	1998-11-25	2016-10-26	US
Verelan PM	Capsule, extended release	200 mg/1	Oral	Kremers Urban	1998-11-25	Not applicable	US
Verelan PM	Capsule, extended release	300 mg/1	Oral	bryant ranch prepack	1998-11-25	Not applicable	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-verap SR	Tablet, extended release	120 mg	Oral	Apotex Corporation	2003-04-24	Not applicable	Canada
Apo-verap SR	Tablet, extended release	180 mg	Oral	Apotex Corporation	2003-04-24	Not applicable	Canada
Apo-verap SR	Tablet, extended release	240 mg	Oral	Apotex Corporation	2003-04-24	Not applicable	Canada
Apo-verap Tab 80mg	Tablet	80 mg	Oral	Apotex Corporation	1989-12-31	Not applicable	Canada
Apo-verap Tablet 120mg	Tablet	120 mg	Oral	Apotex Corporation	1989-12-31	Not applicable	Canada
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31	US
Verapamil	Tablet, film coated, extended release	240 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2016-04-30	US
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2015-12-31	US
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31	US
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-02-05	Not applicable	US
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	Amerincan Health Packaging	2014-01-14	2016-03-31	US
Verapamil	Tablet, film coated, extended release	240 mg/1	Oral	Apotex Corporation	2012-11-19	2016-12-31	US
Verapamil	Tablet, film coated, extended release	180 mg/1	Oral	Unit Dose Services	2012-11-19	Not applicable	US
Verapamil	Tablet, extended release	180 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-08-05	Not applicable	US
Verapamil	Tablet, film coated, extended release	120 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Mylan Pharmaceuticals	1997-02-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Teva	2014-04-07	Not applicable	US
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Rebel Distributors	1995-04-24	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Directrx	2017-03-15	Not applicable	US
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Remedy Repack	2011-11-16	2016-11-02	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Cardinal Health	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Golden State Medical Supply	2014-12-04	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Major	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Remedy Repack	2010-11-22	2016-10-13	US
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Carilion Materials Management	1993-06-29	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	General Injectables & Vaccines	2010-03-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Mylan Pharmaceuticals	2009-12-28	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Physicians Total Care, Inc.	2000-11-28	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-06-04	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Sun Pharmaceutical Industries Limited	2012-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	bryant ranch prepack	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Hospira, Inc.	1998-10-20	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Actavis Pharma Company	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Avera Mc Kennan Hospital	2015-04-06	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Clinical Solutions Wholsesale	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Remedy Repack	2016-07-12	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Remedy Repack	2011-12-07	2016-12-13	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Heritage	2011-01-07	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Cardinal Health	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	A S Medication Solutions	2012-01-01	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Clinical Solutions Wholsesale	2009-09-17	2017-06-23	US
Verapamil Hydrochloride	Capsule, extended release	180 mg/1	Oral	Mylan Pharmaceuticals	1999-05-19	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-11-21	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Mylan Institutional	1998-11-15	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	A S Medication Solutions	2009-09-17	2017-06-20	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Cadila Pharnmaceuticals	2017-05-27	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-09-26	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-01-07	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2012-02-23	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Hospira, Inc.	1987-05-06	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Remedy Repack	2011-12-13	2016-10-26	US
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	Avera Mc Kennan Hospital	2016-07-01	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/301	Oral	Northwind Pharmaceuticals	2014-05-27	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Physicians Total Care, Inc.	1995-04-24	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Cardinal Health	2011-03-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-22	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-12-17	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	1997-09-22	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Remedy Repack	2013-05-14	2017-01-18	US
Verapamil Hydrochloride	Capsule, extended release	100 mg/1	Oral	Physicians Total Care, Inc.	2008-08-07	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	bryant ranch prepack	1992-08-01	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Mylan Institutional	1999-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	A S Medication Solutions	2009-09-17	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Teva	2014-03-10	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Unit Dose Services	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Actavis Pharma Company	1993-06-29	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Red Pharm Drug, Inc.	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Clinical Solutions Wholsesale	1993-06-29	2017-06-24	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-05-04	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Mylan Pharmaceuticals	1997-09-22	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	General Injectables & Vaccines	2010-09-01	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Rebel Distributors	1996-02-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	A S Medication Solutions	2011-01-07	2017-06-20	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-11-01	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Cardinal Health	2011-03-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Golden State Medical Supply	2014-12-04	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Blenheim Pharmacal, Inc.	2011-02-15	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Remedy Repack	2011-07-25	2016-11-02	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Mylan Pharmaceuticals	1989-02-15	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	300 mg/1	Oral	Physicians Total Care, Inc.	2007-12-20	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2012-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Sun Pharmaceutical Industries Limited	2012-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	bryant ranch prepack	1997-10-10	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Mylan Institutional	1996-04-15	Not applicable	US
Verapamil Hydrochloride	Tablet	40 mg/1	Oral	Heritage	2011-01-07	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	A S Medication Solutions	2011-08-05	2017-06-20	US
Verapamil Hydrochloride	Capsule, extended release	240 mg/1	Oral	Mylan Pharmaceuticals	1999-05-19	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	A S Medication Solutions	1986-10-01	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Proficient Rx LP	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2012-02-23	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Remedy Repack	2013-03-14	2016-12-31	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Physicians Total Care, Inc.	1996-02-05	Not applicable	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Cardinal Health	2011-03-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Major	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	1996-03-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Remedy Repack	2013-05-15	2017-01-12	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Physicians Total Care, Inc.	1996-01-15	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	120 mg/1	Oral	Sun Pharmaceutical Industries Limited	2012-01-01	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	bryant ranch prepack	2010-04-20	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Actavis Pharma Company	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet	120 mg/1	Oral	Remedy Repack	2014-06-27	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	A S Medication Solutions	2011-08-05	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Mylan Pharmaceuticals	1996-03-25	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Teva	2014-01-29	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Clinical Solutions Wholsesale	2011-08-05	2017-06-23	US
Verapamil Hydrochloride	Capsule, extended release	120 mg/1	Oral	Mylan Pharmaceuticals	1999-05-19	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Mylan Institutional	1998-04-17	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Cadila Pharnmaceuticals	2017-05-27	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Clinical Solutions Wholsesale	1986-10-01	2017-06-24	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-10-17	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	180 mg/1	Oral	Remedy Repack	2011-07-21	2017-11-09	US
Verapamil Hydrochloride	Injection, solution	2.5 mg/mL	Intravenous	Hospira, Inc.	1987-05-06	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Rebel Distributors	2010-04-20	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	40 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-06	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	A S Medication Solutions	1986-10-01	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Cardinal Health	2012-07-12	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Golden State Medical Supply	2014-12-04	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Blenheim Pharmacal, Inc.	2010-08-20	Not applicable	US
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Remedy Repack	2011-08-08	2016-11-04	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Verapamil Hydrochloride	Tablet	80 mg/1	Oral	Heritage	2011-01-07	Not applicable	US
Verapamil Hydrochloride	Capsule, extended release	200 mg/1	Oral	Physicians Total Care, Inc.	2010-05-17	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	A S Medication Solutions	2012-01-01	2017-06-20	US
Verapamil Hydrochloride	Tablet	240 mg/1	Oral	Remedy Repack	2012-10-02	2016-10-13	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Physicians Total Care, Inc.	2000-05-09	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	240 mg/1	Oral	Unit Dose Services	2009-09-17	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	120 mg/1	Oral	A S Medication Solutions	2011-08-05	2017-06-20	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2014-01-29	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated, extended release	180 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-08-05	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	120 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1989-02-15	Not applicable	US
Verapamil Hydrochloride	Tablet, film coated	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	1986-10-01	Not applicable	US
Verapamil Hydrochloride	Tablet, extended release	240 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Verapamil Hydrochloride PM	Capsule, extended release	100 mg/1	Oral	Mylan Pharmaceuticals	2007-08-09	Not applicable	US
Verapamil Hydrochloride PM	Capsule, extended release	200 mg/1	Oral	Mylan Pharmaceuticals	2007-08-09	Not applicable	US
Verapamil Hydrochloride PM	Capsule, extended release	100 mg/1	Oral	Avera Mc Kennan Hospital	2015-06-25	Not applicable	US
Verapamil Hydrochloride PM	Capsule, extended release	300 mg/1	Oral	Mylan Pharmaceuticals	2007-08-09	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Bosoptin	Bosnalijek
Isoptin	Abbott
Verisop	Gerard
Vermin	Ratiopharm
Vermine	Pharmasant
Verogalid	Ivax
Verogalid ER	Ivax
Verpamil	Mylan
Vertab	Trinity-Chiesi
Vetrimil	CCPC
Zolvera	Rosemont

Brand mixtures

Name	Labeller	Ingredients
Tarka	Physicians Total Care, Inc.	Trandolapril Verapamil
Trandolapril and Verapamil Hydrochloride	Glenmark Pharmaceuticals Inc.,Usa	Trandolapril Verapamil
Trandolapril and Verapamil Hydrochloride ER	Greenstone, Llc	Trandolapril Verapamil

Categories

UNII

CJ0O37KU29

CAS number

52-53-9

Weight

Average: 454.6016
Monoisotopic: 454.283157714

Chemical Formula

C₂₇H₃₈N₂O₄

InChI Key

SGTNSNPWRIOYBX-UHFFFAOYSA-N

InChI

InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3

IUPAC Name

2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile

SMILES

COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1

Pharmacology

Indication

For the treatment of hypertension, angina, and cluster headache prophylaxis.

Structured Indications

Pharmacodynamics

Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.

Mechanism of action

Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1C	Protein	yes	inhibitor	Human	Q13936	details
Voltage-dependent L-type calcium channel subunit alpha-1D	Protein	yes	inhibitor	Human	Q01668	details
Voltage-dependent L-type calcium channel subunit alpha-1F	Protein	yes	inhibitor	Human	O60840	details
Voltage-dependent L-type calcium channel subunit alpha-1S	Protein	yes	inhibitor	Human	Q13698	details
Voltage-dependent L-type calcium channel subunit beta-1	Protein	yes	inhibitor	Human	Q02641	details
Voltage-dependent L-type calcium channel subunit beta-2	Protein	yes	inhibitor	Human	Q08289	details
Voltage-dependent L-type calcium channel subunit beta-3	Protein	yes	inhibitor	Human	P54284	details
Voltage-dependent L-type calcium channel subunit beta-4	Protein	yes	inhibitor	Human	O00305	details
Voltage-dependent T-type calcium channel subunit alpha-1I	Protein	unknown	inhibitor	Human	Q9P0X4	details
Voltage-dependent T-type calcium channel subunit alpha-1G	Protein	unknown	inhibitor	Human	O43497	details
Voltage-dependent N-type calcium channel subunit alpha-1B	Protein	unknown	inhibitor	Human	Q00975	details
Voltage-dependent P/Q-type calcium channel subunit alpha-1A	Protein	unknown	inhibitor	Human	O00555	details
Potassium voltage-gated channel subfamily H member 2	Protein	unknown	inhibitor	Human	Q12809	details
Sodium channel protein type 5 subunit alpha	Protein	unknown	other	Human	Q14524	details
ATP-sensitive inward rectifier potassium channel 11	Protein	unknown	inhibitor	Human	Q14654	details
Sodium-dependent serotonin transporter	Protein	unknown	other/unknown	Human	P31645	details

Absorption

90%

Volume of distribution

Not Available

Protein binding

90%

Metabolism

Substrate	Enzymes	Product
Verapamil	Cytochrome P450 2C8 Cytochrome P450 2C18 Cytochrome P450 2C9	O-Desmethylverapamil (D-702)	Details
Verapamil	Cytochrome P450 2C8	Verapamil metabolite D-617	Details
Verapamil	Cytochrome P450 2C8 Cytochrome P450 3A4 Cytochrome P450 3A5 Cytochrome P450 1A2	Norverapamil	Details
Verapamil	Cytochrome P450 2C8 Cytochrome P450 2C9	O-Desmethylverapamil (D-703)	Details
O-Desmethylverapamil (D-702)	Cytochrome P450 3A5 Cytochrome P450 3A4	Verapamil metabolite D-620	Details
Verapamil metabolite D-617	Cytochrome P450 3A4 Cytochrome P450 3A5	Verapamil metabolite D-620	Details
Verapamil metabolite D-617	Not Available	Verapamil metabolite PR-25	Details
Norverapamil	Cytochrome P450 2C8	Verapamil metabolite D-715 (PR-22)	Details
Norverapamil	Cytochrome P450 2C8	Verapamil metabolite D-620	Details

Route of elimination

Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.

Half life

2.8-7.4 hours

Clearance

Not Available

Toxicity

LD₅₀=8 mg/kg (i.v. in mice)

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Verapamil Action Pathway	Drug action	SMP00375

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Beta-1 adrenergic receptor	---	(C;C) / (C;G)	G > C	Effect Directly Studied	Better response to drug therapy	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The metabolism of Verapamil can be decreased when combined with 1,10-Phenanthroline.	Experimental
2-HYDROXY-1,4-NAPHTHOQUINONE	The risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Verapamil.	Experimental
3,4-Dichloroisocoumarin	The metabolism of Verapamil can be decreased when combined with 3,4-Dichloroisocoumarin.	Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE	The metabolism of Verapamil can be decreased when combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.	Experimental
Abiraterone	The serum concentration of Verapamil can be increased when it is combined with Abiraterone.	Approved
Acebutolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.	Approved
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Verapamil.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Verapamil.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Acetazolamide.	Approved, Vet Approved
Acetyldigitoxin	Verapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Verapamil.	Approved, Vet Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Verapamil.	Approved
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Verapamil.	Approved
Albendazole	The metabolism of Albendazole can be decreased when combined with Verapamil.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Verapamil.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.	Approved
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Verapamil.	Experimental
Alectinib	The serum concentration of Verapamil can be increased when it is combined with Alectinib.	Approved
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Verapamil.	Approved, Illicit
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Verapamil.	Approved, Investigational
Aliskiren	The serum concentration of Aliskiren can be increased when it is combined with Verapamil.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Verapamil.	Approved, Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Verapamil.	Approved
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Verapamil.	Approved, Investigational
Alogliptin	The metabolism of Verapamil can be decreased when combined with Alogliptin.	Approved
Alosetron	The metabolism of Alosetron can be decreased when combined with Verapamil.	Approved, Withdrawn
Alpha-1-proteinase inhibitor	The metabolism of Verapamil can be decreased when combined with Alpha-1-proteinase inhibitor.	Approved
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Verapamil.	Approved, Illicit, Investigational
Alprenolol	Verapamil may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Amantadine	The serum concentration of Verapamil can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Verapamil.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Verapamil.	Approved
Amifostine	The risk or severity of adverse effects can be increased when Verapamil is combined with Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.	Approved
Aminohippuric acid	The serum concentration of Verapamil can be increased when it is combined with Aminohippuric acid.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Verapamil.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Verapamil.	Approved
Aminosalicylic Acid	Verapamil may increase the anticoagulant activities of Aminosalicylic Acid.	Approved
Amiodarone	Verapamil may increase the bradycardic activities of Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Verapamil.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Verapamil.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Verapamil.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.	Approved, Investigational
Amprenavir	The metabolism of Verapamil can be decreased when combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Verapamil can be increased when it is combined with Amsacrine.	Approved
Amyl Nitrite	The risk or severity of adverse effects can be increased when Verapamil is combined with Amyl Nitrite.	Approved
Anidulafungin	The risk or severity of adverse effects can be increased when Anidulafungin is combined with Verapamil.	Approved, Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Verapamil.	Approved
Antithrombin III human	The metabolism of Verapamil can be decreased when combined with Antithrombin III human.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Verapamil.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Verapamil is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Verapamil is combined with Apraclonidine.	Approved
Apremilast	The metabolism of Apremilast can be decreased when combined with Verapamil.	Approved, Investigational
Aprepitant	The serum concentration of Verapamil can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprotinin	The metabolism of Verapamil can be decreased when combined with Aprotinin.	Approved, Withdrawn
Argatroban	The metabolism of Verapamil can be decreased when combined with Argatroban.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Verapamil.	Approved, Investigational
Armodafinil	The metabolism of Verapamil can be decreased when combined with Armodafinil.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Arotinolol.	Approved
Arsenic trioxide	The serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.	Approved, Investigational
Artemether	The risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.	Approved
Asenapine	The metabolism of Asenapine can be decreased when combined with Verapamil.	Approved
Astemizole	The metabolism of Astemizole can be decreased when combined with Verapamil.	Approved, Withdrawn
Atazanavir	The metabolism of Verapamil can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Verapamil.	Approved
Atomoxetine	The metabolism of Verapamil can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Verapamil can be increased when it is combined with Atorvastatin.	Approved
Atracurium besylate	Verapamil may increase the neuromuscular blocking activities of Atracurium besylate.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Verapamil.	Approved
Axitinib	The metabolism of Axitinib can be decreased when combined with Verapamil.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Verapamil.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.	Approved
Azithromycin	The metabolism of Azithromycin can be decreased when combined with Verapamil.	Approved
Bafilomycin A1	The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Verapamil.	Experimental
Balsalazide	Verapamil may increase the anticoagulant activities of Balsalazide.	Approved, Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Verapamil.	Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Verapamil.	Experimental
Barbital	Barbital may increase the hypotensive activities of Verapamil.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Barnidipine.	Approved
Batimastat	The metabolism of Verapamil can be decreased when combined with Batimastat.	Experimental
Bedaquiline	The metabolism of Bedaquiline can be decreased when combined with Verapamil.	Approved
Befunolol	Verapamil may increase the hypotensive activities of Befunolol.	Experimental
Benazepril	The metabolism of Verapamil can be decreased when combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.	Approved
Benzamidine	The metabolism of Verapamil can be decreased when combined with Benzamidine.	Experimental
Benzocaine	The serum concentration of Verapamil can be increased when it is combined with Benzocaine.	Approved
Benzoic Acid	The risk or severity of adverse effects can be increased when Benzoic Acid is combined with Verapamil.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Verapamil.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Verapamil.	Approved
Bepridil	The serum concentration of Verapamil can be increased when it is combined with Bepridil.	Approved, Withdrawn
Beractant	Verapamil may increase the bradycardic activities of Beractant.	Approved
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Verapamil.	Approved, Vet Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.	Approved
Bevantolol	Verapamil may increase the hypotensive activities of Bevantolol.	Approved
Bexarotene	The serum concentration of Verapamil can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Verapamil.	Approved
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Verapamil.	Approved
Bifonazole	The risk or severity of adverse effects can be increased when Bifonazole is combined with Verapamil.	Approved
Biperiden	The serum concentration of Verapamil can be increased when it is combined with Biperiden.	Approved
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.	Approved
Bivalirudin	The metabolism of Verapamil can be decreased when combined with Bivalirudin.	Approved, Investigational
Boceprevir	The metabolism of Verapamil can be decreased when combined with Boceprevir.	Approved, Investigational
Bopindolol	Verapamil may increase the hypotensive activities of Bopindolol.	Approved
Bortezomib	The metabolism of Verapamil can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Verapamil.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Verapamil.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Verapamil.	Approved
Bretylium	Bretylium may increase the bradycardic activities of Verapamil.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.	Approved
Brinzolamide	The metabolism of Brinzolamide can be decreased when combined with Verapamil.	Approved
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Verapamil.	Approved, Illicit
Bromocriptine	The metabolism of Bromocriptine can be decreased when combined with Verapamil.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Verapamil.	Approved
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Verapamil.	Approved
Budesonide	The metabolism of Budesonide can be decreased when combined with Verapamil.	Approved
Bufuralol	Verapamil may increase the hypotensive activities of Bufuralol.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.	Approved
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Verapamil.	Approved, Investigational
Bupranolol	Verapamil may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Verapamil.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Verapamil.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Verapamil.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Verapamil.	Approved, Investigational
Butenafine	The risk or severity of adverse effects can be increased when Butenafine is combined with Verapamil.	Approved
Butoconazole	The risk or severity of adverse effects can be increased when Butoconazole is combined with Verapamil.	Approved
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Verapamil.	Approved
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Verapamil.	Approved
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Verapamil.	Approved
Caffeine	The metabolism of Caffeine can be decreased when combined with Verapamil.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Verapamil.	Approved, Nutraceutical
Calcium	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium.	Nutraceutical
Calcium Acetate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.	Approved
Calcium carbonate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium carbonate.	Approved
Calcium Chloride	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.	Approved
Calcium citrate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Calfactant	Verapamil may increase the bradycardic activities of Calfactant.	Approved
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Verapamil.	Experimental
Canagliflozin	The risk or severity of adverse effects can be increased when Verapamil is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan.	Approved
Candicidin	The risk or severity of adverse effects can be increased when Candicidin is combined with Verapamil.	Withdrawn
Candoxatril	The metabolism of Verapamil can be decreased when combined with Candoxatril.	Experimental
Candoxatrilat	The metabolism of Verapamil can be decreased when combined with Candoxatrilat.	Experimental
Capecitabine	The metabolism of Verapamil can be decreased when combined with Capecitabine.	Approved, Investigational
Capric acid	The risk or severity of adverse effects can be increased when Decanoic Acid is combined with Verapamil.	Experimental
Captopril	The metabolism of Verapamil can be decreased when combined with Captopril.	Approved
Carbamazepine	The serum concentration of Carbamazepine can be increased when it is combined with Verapamil.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Verapamil is combined with Carbetocin.	Approved
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Verapamil.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Verapamil.	Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Verapamil.	Approved
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Verapamil.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.	Approved, Investigational
Caspofungin	The risk or severity of adverse effects can be increased when Caspofungin is combined with Verapamil.	Approved
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Verapamil.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Verapamil.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Verapamil.	Approved, Vet Approved
Ceritinib	Verapamil may increase the bradycardic activities of Ceritinib.	Approved
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Verapamil.	Withdrawn
Cerulenin	The risk or severity of adverse effects can be increased when Cerulenin is combined with Verapamil.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Verapamil.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.	Approved
Chloramphenicol	The metabolism of Verapamil can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Verapamil.	Approved, Illicit
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Verapamil.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.	Approved, Vet Approved
Chloroxine	The risk or severity of adverse effects can be increased when Chloroxine is combined with Verapamil.	Approved
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Verapamil.	Approved
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Verapamil.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Verapamil can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.	Approved
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Verapamil.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Verapamil.	Approved, Nutraceutical
Cholesterol	The serum concentration of Verapamil can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	Verapamil may decrease the excretion rate of Cholic Acid which could result in a higher serum level.	Approved
Chymostatin	The metabolism of Verapamil can be decreased when combined with Chymostatin.	Experimental
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Verapamil.	Approved, Investigational
Ciclopirox	The risk or severity of adverse effects can be increased when Ciclopirox is combined with Verapamil.	Approved, Investigational
Cilastatin	The metabolism of Verapamil can be decreased when combined with Cilastatin.	Approved
Cilazapril	The metabolism of Verapamil can be decreased when combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Cilnidipine.	Approved
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Verapamil.	Approved
Cimetidine	The serum concentration of Verapamil can be increased when it is combined with Cimetidine.	Approved
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Verapamil.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be decreased when it is combined with Verapamil.	Approved, Investigational
Cisapride	The metabolism of Cisapride can be decreased when combined with Verapamil.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be decreased when it is combined with Verapamil.	Approved
Citalopram	The metabolism of Citalopram can be decreased when combined with Verapamil.	Approved
Clarithromycin	The metabolism of Verapamil can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Verapamil can be decreased when combined with Clemastine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.	Approved
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Verapamil.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Verapamil.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Verapamil is combined with Clofarabine.	Approved, Investigational
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Verapamil.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Verapamil.	Approved
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Verapamil.	Approved, Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Verapamil.	Approved, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Verapamil.	Approved, Illicit
Clonidine	Clonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.	Approved, Nutraceutical
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Verapamil.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Verapamil.	Approved, Illicit
Clotrimazole	The risk or severity of adverse effects can be increased when Clotrimazole is combined with Verapamil.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Verapamil.	Approved
Cobicistat	The metabolism of Verapamil can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Verapamil.	Approved
Cocaine	The metabolism of Cocaine can be decreased when combined with Verapamil.	Approved, Illicit
Codeine	The metabolism of Codeine can be decreased when combined with Verapamil.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Verapamil.	Approved
Colforsin	The serum concentration of Verapamil can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Verapamil can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated Equine Estrogens can be decreased when combined with Verapamil.	Approved
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Verapamil.	Approved
Crizotinib	The metabolism of Crizotinib can be decreased when combined with Verapamil.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Verapamil.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
Cyclosporine	The risk or severity of adverse effects can be increased when Cyclosporine is combined with Verapamil.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Verapamil can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Verapamil.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Verapamil.	Approved
Dabrafenib	The serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The metabolism of Daclatasvir can be decreased when combined with Verapamil.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be decreased when it is combined with Verapamil.	Approved
Dantrolene	Dantrolene may increase the hyperkalemic activities of Verapamil.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Verapamil is combined with Dapagliflozin.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Verapamil.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Verapamil.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Verapamil.	Approved, Investigational
Darunavir	The metabolism of Verapamil can be decreased when combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Verapamil.	Approved
Dasatinib	The serum concentration of Verapamil can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Verapamil.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Verapamil.	Approved
Deferasirox	The serum concentration of Verapamil can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Verapamil can be decreased when combined with Delavirdine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Verapamil is combined with Desflurane.	Approved
Desipramine	The serum concentration of Verapamil can be increased when it is combined with Desipramine.	Approved
Deslanoside	Verapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.	Approved
Desloratadine	The serum concentration of Verapamil can be increased when it is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Verapamil.	Approved
Dexamethasone	The serum concentration of Verapamil can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.	Approved, Vet Approved
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Verapamil.	Approved
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.	Approved, Illicit, Withdrawn
Diazepam	The metabolism of Diazepam can be decreased when combined with Verapamil.	Approved, Illicit, Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Verapamil.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Verapamil.	Approved
Diflunisal	Verapamil may increase the anticoagulant activities of Diflunisal.	Approved
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Verapamil.	Approved
Digoxin	The metabolism of Digoxin can be decreased when combined with Verapamil.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Verapamil.	Approved, Illicit
Dihydroergotamine	The metabolism of Verapamil can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Verapamil.	Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Verapamil.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.	Approved
Disopyramide	The risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Verapamil.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Verapamil.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Verapamil.	Approved
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Verapamil.	Approved
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Verapamil.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Verapamil.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Verapamil.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Verapamil.	Approved
Doxepin	The metabolism of Doxepin can be decreased when combined with Verapamil.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Verapamil.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Verapamil.	Approved, Investigational
Doxycycline	The metabolism of Verapamil can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Verapamil.	Approved, Illicit
Dronedarone	Verapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.	Approved
Duloxetine	Verapamil may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dutasteride	The metabolism of Dutasteride can be decreased when combined with Verapamil.	Approved, Investigational
Ecabet	The metabolism of Verapamil can be decreased when combined with Ecabet.	Approved, Investigational
Econazole	The risk or severity of adverse effects can be increased when Econazole is combined with Verapamil.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Verapamil.	Approved
Efavirenz	The serum concentration of Verapamil can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The risk or severity of adverse effects can be increased when Efinaconazole is combined with Verapamil.	Approved
Efonidipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Efonidipine.	Approved
Elafin	The metabolism of Verapamil can be decreased when combined with Elafin.	Investigational
Elbasvir	The serum concentration of Verapamil can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Verapamil.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Verapamil.	Approved
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Verapamil.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.	Approved
Enalapril	The metabolism of Verapamil can be decreased when combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The metabolism of Verapamil can be decreased when combined with Enalaprilat.	Approved
Enalkiren	The metabolism of Verapamil can be decreased when combined with Enalkiren.	Experimental
Enzalutamide	The serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The metabolism of Epinastine can be decreased when combined with Verapamil.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Verapamil.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Verapamil is combined with Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Verapamil.	Approved, Nutraceutical
Ergoloid mesylate	The metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.	Approved
Ergonovine	The metabolism of Ergonovine can be decreased when combined with Verapamil.	Approved
Ergotamine	The metabolism of Ergotamine can be decreased when combined with Verapamil.	Approved
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Verapamil.	Approved, Investigational
Erythromycin	The metabolism of Verapamil can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Verapamil.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Verapamil can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.	Approved
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Verapamil.	Approved, Investigational
Estazolam	The metabolism of Estazolam can be decreased when combined with Verapamil.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Verapamil.	Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Verapamil.	Approved, Vet Approved
Estrone	The metabolism of Estrone can be decreased when combined with Verapamil.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Verapamil.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Verapamil.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.	Approved
Ethanol	The serum concentration of Ethanol can be increased when it is combined with Verapamil.	Approved
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Verapamil.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Verapamil.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Verapamil.	Approved, Illicit
Etonogestrel	The metabolism of Etonogestrel can be decreased when combined with Verapamil.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Verapamil.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Verapamil.	Approved, Investigational
Etravirine	The serum concentration of Verapamil can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Verapamil.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Verapamil.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Verapamil.	Approved
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Verapamil.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Verapamil.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.	Approved, Investigational
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Verapamil.	Approved
Fenoldopam	The risk or severity of adverse effects can be increased when Verapamil is combined with Fenoldopam.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Verapamil.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.	Approved
Fexofenadine	The bioavailability of Fexofenadine can be increased when combined with Verapamil.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Verapamil.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Fimasartan.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Verapamil.	Approved
Fingolimod	Verapamil may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Flecainide	The risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Verapamil.	Approved
Floxuridine	The metabolism of Verapamil can be decreased when combined with Floxuridine.	Approved
Fluconazole	The serum concentration of Verapamil can be increased when it is combined with Fluconazole.	Approved
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Verapamil.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Verapamil.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Verapamil.	Approved, Illicit
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Verapamil.	Approved
Fluorouracil	The metabolism of Verapamil can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	The metabolism of Fluoxetine can be decreased when combined with Verapamil.	Approved, Vet Approved
Flupentixol	The serum concentration of Verapamil can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Verapamil can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Verapamil.	Approved, Illicit
Flutamide	The metabolism of Flutamide can be decreased when combined with Verapamil.	Approved
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Verapamil.	Approved
Fluticasone Propionate	The metabolism of Fluticasone Propionate can be decreased when combined with Verapamil.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Verapamil.	Approved
Fluvoxamine	The metabolism of Verapamil can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Verapamil can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The metabolism of Verapamil can be decreased when combined with Fosinopril.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.	Approved
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Verapamil.	Approved, Investigational
Furosemide	The risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.	Approved
Gabexate	The metabolism of Verapamil can be decreased when combined with Gabexate.	Investigational
Galantamine	The metabolism of Galantamine can be decreased when combined with Verapamil.	Approved
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Verapamil.	Approved, Investigational
Geldanamycin	The metabolism of Verapamil can be decreased when combined with Geldanamycin.	Experimental
Gemcitabine	The serum concentration of Gemcitabine can be decreased when it is combined with Verapamil.	Approved
Gemfibrozil	The metabolism of Verapamil can be decreased when combined with Gemfibrozil.	Approved
Genistein	The serum concentration of Verapamil can be increased when it is combined with Genistein.	Investigational
Glipizide	The metabolism of Glipizide can be decreased when combined with Verapamil.	Approved
Glyburide	The metabolism of Glyburide can be decreased when combined with Verapamil.	Approved
Glyphosate	The risk or severity of adverse effects can be increased when Glyphosate is combined with Verapamil.	Experimental
GM6001	The metabolism of Verapamil can be decreased when combined with GM6001.	Experimental
Gramicidin D	The serum concentration of Verapamil can be increased when it is combined with Gramicidin D.	Approved
Granisetron	The metabolism of Granisetron can be decreased when combined with Verapamil.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Verapamil.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Verapamil.	Withdrawn
Griseofulvin	The risk or severity of adverse effects can be increased when Griseofulvin is combined with Verapamil.	Approved, Vet Approved
Guanfacine	The risk or severity of adverse effects can be increased when Verapamil is combined with Guanfacine.	Approved, Investigational
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Verapamil.	Approved
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Verapamil.	Approved
Haloprogin	The risk or severity of adverse effects can be increased when Haloprogin is combined with Verapamil.	Approved, Withdrawn
Halothane	The metabolism of Halothane can be decreased when combined with Verapamil.	Approved, Vet Approved
Hexetidine	The risk or severity of adverse effects can be increased when Hexetidine is combined with Verapamil.	Approved
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Verapamil.	Approved
Histamine	The metabolism of Histamine Phosphate can be decreased when combined with Verapamil.	Approved, Investigational
Hydralazine	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The serum concentration of Hydrocodone can be increased when it is combined with Verapamil.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Verapamil.	Approved, Vet Approved
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Verapamil is combined with Hydroflumethiazide.	Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Verapamil.	Approved, Illicit
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.	Approved
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Verapamil.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Verapamil.	Approved
Idelalisib	The serum concentration of Verapamil can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.	Approved
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Verapamil.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Verapamil is combined with Iloprost.	Approved, Investigational
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Verapamil.	Approved
Imipramine	The metabolism of Imipramine can be decreased when combined with Verapamil.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Verapamil.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Verapamil.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.	Approved
Indenolol	Verapamil may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Verapamil can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Verapamil.	Approved, Investigational
Indoramin	Indoramin may increase the hypotensive activities of Verapamil.	Withdrawn
Ipratropium bromide	The metabolism of Ipratropium bromide can be decreased when combined with Verapamil.	Approved
Irbesartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.	Approved, Investigational
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Verapamil.	Approved, Investigational
Isavuconazonium	The metabolism of Verapamil can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Verapamil is combined with Isocarboxazid.	Approved
Isoconazole	The risk or severity of adverse effects can be increased when Isoconazole is combined with Verapamil.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Verapamil is combined with Isoflurane.	Approved, Vet Approved
Isoflurophate	The metabolism of Verapamil can be decreased when combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The metabolism of Verapamil can be decreased when combined with Isoniazid.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Verapamil is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Verapamil.	Approved
Itraconazole	The metabolism of Verapamil can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Verapamil.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Verapamil.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Verapamil.	Approved, Vet Approved
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Verapamil.	Approved, Investigational
Ixazomib	The metabolism of Verapamil can be decreased when combined with Ixazomib.	Approved
Josamycin	The metabolism of Verapamil can be decreased when combined with Josamycin.	Approved
Ketamine	The metabolism of Ketamine can be decreased when combined with Verapamil.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Verapamil.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Verapamil.	Approved
Ketoconazole	The metabolism of Verapamil can be decreased when combined with Ketoconazole.	Approved, Investigational
Kitasamycin	The metabolism of Verapamil can be decreased when combined with Kitasamycin.	Experimental
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Verapamil.	Approved
Lacidipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Lacidipine.	Approved
Lacosamide	Verapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Verapamil.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Verapamil.	Approved, Investigational
Lanreotide	Verapamil may increase the bradycardic activities of Lanreotide.	Approved
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Verapamil.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Verapamil.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Verapamil.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Verapamil.	Approved
Leflunomide	The metabolism of Verapamil can be decreased when combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.	Approved
Lenvatinib	The metabolism of Lenvatinib can be decreased when combined with Verapamil.	Approved
Lepirudin	The metabolism of Verapamil can be decreased when combined with Lepirudin.	Approved
Lercanidipine	The metabolism of Lercanidipine can be decreased when combined with Verapamil.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Verapamil.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Verapamil.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Levobunolol.	Approved
Levobupivacaine	The metabolism of Levobupivacaine can be decreased when combined with Verapamil.	Approved
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Verapamil.	Approved
Levodopa	Verapamil may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Verapamil.	Approved
Levonorgestrel	The metabolism of Levonorgestrel can be decreased when combined with Verapamil.	Approved, Investigational
Levosimendan	The risk or severity of adverse effects can be increased when Verapamil is combined with Levosimendan.	Approved, Investigational
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Verapamil.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Verapamil.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Verapamil.	Approved
Liothyronine	The serum concentration of Verapamil can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Verapamil can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The metabolism of Verapamil can be decreased when combined with Lisinopril.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Verapamil.	Approved
Lithium	Verapamil may increase the neurotoxic activities of Lithium.	Approved
Lofexidine	The risk or severity of adverse effects can be increased when Verapamil is combined with Lofexidine.	Approved, Investigational
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Verapamil.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Verapamil.	Approved
Lopinavir	The metabolism of Verapamil can be decreased when combined with Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Verapamil.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Verapamil.	Approved
Losartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Verapamil.	Approved, Investigational
Lucinactant	Verapamil may increase the bradycardic activities of Lucinactant.	Approved
Luliconazole	The serum concentration of Verapamil can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Verapamil can be increased when it is combined with Lumacaftor.	Approved
Lumefantrine	The metabolism of Lumefantrine can be decreased when combined with Verapamil.	Approved
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Verapamil.	Approved
Macitentan	The metabolism of Macitentan can be decreased when combined with Verapamil.	Approved
Magnesium Hydroxide	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.	Approved
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.	Approved, Vet Approved
Mannitol	The risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.	Approved, Investigational
Maprotiline	The serum concentration of Verapamil can be increased when it is combined with Maprotiline.	Approved
Maraviroc	The metabolism of Maraviroc can be decreased when combined with Verapamil.	Approved, Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Verapamil.	Approved, Vet Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.	Approved
Medroxyprogesterone acetate	The metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.	Approved, Investigational
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Verapamil.	Approved
Megestrol acetate	The serum concentration of Verapamil can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Verapamil.	Approved, Vet Approved
Meprobamate	The serum concentration of Verapamil can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	Verapamil may increase the anticoagulant activities of Mesalazine.	Approved
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.	Approved
Methadone	The metabolism of Methadone can be decreased when combined with Verapamil.	Approved
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Verapamil.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Verapamil.	Approved
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Verapamil.	Approved
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Verapamil.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Verapamil.	Approved, Vet Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.	Approved
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Verapamil.	Approved
Methylprednisolone	The metabolism of Methylprednisolone can be decreased when combined with Verapamil.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Verapamil.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Verapamil.	Approved, Investigational
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Verapamil.	Approved
Mevastatin	The risk or severity of adverse effects can be increased when Mevastatin is combined with Verapamil.	Experimental
Mexiletine	The metabolism of Verapamil can be decreased when combined with Mexiletine.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Verapamil.	Approved
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Verapamil.	Withdrawn
Micafungin	The risk or severity of adverse effects can be increased when Micafungin is combined with Verapamil.	Approved, Investigational
Miconazole	The risk or severity of adverse effects can be increased when Miconazole is combined with Verapamil.	Approved, Investigational, Vet Approved
Midazolam	The metabolism of Midazolam can be decreased when combined with Verapamil.	Approved, Illicit
Midodrine	Verapamil may increase the bradycardic activities of Midodrine.	Approved
Mifepristone	The serum concentration of Verapamil can be increased when it is combined with Mifepristone.	Approved, Investigational
Miltefosine	The risk or severity of adverse effects can be increased when Miltefosine is combined with Verapamil.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.	Approved
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Verapamil.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Verapamil.	Approved
Mitomycin	The serum concentration of Verapamil can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Verapamil can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be decreased when it is combined with Verapamil.	Approved, Investigational
Mivacurium	Verapamil may increase the neuromuscular blocking activities of Mivacurium.	Approved
Moclobemide	The metabolism of Verapamil can be decreased when combined with Moclobemide.	Approved
Modafinil	The serum concentration of Verapamil can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The metabolism of Verapamil can be decreased when combined with Moexipril.	Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Verapamil.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Verapamil.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Verapamil is combined with Moxonidine.	Approved
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.	Approved, Investigational
Myxothiazol	The risk or severity of adverse effects can be increased when Myxothiazol is combined with Verapamil.	Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	The metabolism of Verapamil can be decreased when combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.	Experimental
Nabilone	The risk or severity of adverse effects can be increased when Verapamil is combined with Nabilone.	Approved, Investigational
Nadolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.	Approved
Nafamostat	The metabolism of Verapamil can be decreased when combined with Nafamostat.	Approved, Investigational
Nafcillin	The metabolism of Verapamil can be increased when combined with Nafcillin.	Approved
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Verapamil.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Verapamil.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Verapamil.	Approved, Vet Approved
Naltrexone	The serum concentration of Verapamil can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Verapamil can be increased when it is combined with Naringenin.	Experimental
Natamycin	The risk or severity of adverse effects can be increased when Natamycin is combined with Verapamil.	Approved
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Verapamil.	Approved, Investigational
NCX 4016	The metabolism of Verapamil can be decreased when combined with NCX 4016.	Investigational
Nebivolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Verapamil can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Verapamil can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Verapamil can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nesiritide	The risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.	Approved, Investigational
Netupitant	The serum concentration of Verapamil can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Verapamil can be increased when combined with Nevirapine.	Approved
Nicardipine	The metabolism of Verapamil can be decreased when combined with Nicardipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Verapamil.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Verapamil.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Verapamil is combined with Nifedipine.	Approved
Nilotinib	The metabolism of Nilotinib can be decreased when combined with Verapamil.	Approved, Investigational
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Verapamil.	Approved
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Verapamil.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Verapamil.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Verapamil.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Verapamil.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Verapamil.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Verapamil is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	Verapamil may increase the hypotensive activities of Nitroprusside.	Approved
Nitroxoline	The risk or severity of adverse effects can be increased when Nitroxoline is combined with Verapamil.	Approved
Nizatidine	The serum concentration of Nizatidine can be decreased when it is combined with Verapamil.	Approved
Norethisterone	The metabolism of Norethisterone can be decreased when combined with Verapamil.	Approved
Norgestrel	The metabolism of Norgestrel can be decreased when combined with Verapamil.	Approved
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Verapamil.	Approved
Nystatin	The risk or severity of adverse effects can be increased when Nystatin is combined with Verapamil.	Approved, Vet Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Verapamil is combined with Obinutuzumab.	Approved
Octreotide	Octreotide may increase the bradycardic activities of Verapamil.	Approved, Investigational
Olanzapine	The serum concentration of Olanzapine can be decreased when it is combined with Verapamil.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Verapamil.	Approved
Oleandrin	Verapamil may increase the atrioventricular blocking (AV block) activities of Anvirzel.	Experimental
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.	Approved, Investigational
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Verapamil.	Approved
Olsalazine	Verapamil may increase the anticoagulant activities of Olsalazine.	Approved
Omapatrilat	The metabolism of Verapamil can be decreased when combined with Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be decreased when it is combined with Verapamil.	Approved
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Verapamil.	Approved
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Verapamil.	Approved
Osimertinib	The serum concentration of Verapamil can be increased when it is combined with Osimertinib.	Approved
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Verapamil.	Approved
Ouabain	Verapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.	Approved
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Verapamil.	Approved
Oxiconazole	The risk or severity of adverse effects can be increased when Oxiconazole is combined with Verapamil.	Approved
Oxprenolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Oxprenolol.	Approved
Oxybutynin	The metabolism of Oxybutynin can be decreased when combined with Verapamil.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
P-Nitrophenol	The serum concentration of Verapamil can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Verapamil.	Approved, Vet Approved
Palbociclib	The serum concentration of Verapamil can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Verapamil can be increased when it is combined with Palmitic Acid.	Experimental
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Verapamil.	Approved, Investigational
Panobinostat	The metabolism of Panobinostat can be decreased when combined with Verapamil.	Approved, Investigational
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Verapamil.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Verapamil.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Verapamil.	Approved
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Verapamil.	Approved
Paricalcitol	The metabolism of Paricalcitol can be decreased when combined with Verapamil.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Verapamil.	Approved
Paroxetine	The serum concentration of Verapamil can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	Verapamil may increase the bradycardic activities of Pasireotide.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Verapamil.	Approved
Peginterferon alfa-2b	The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Penbutolol.	Approved, Investigational
Pentamidine	The risk or severity of adverse effects can be increased when Pentamidine is combined with Verapamil.	Approved
Pentobarbital	The metabolism of Verapamil can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Verapamil.	Approved
Pergolide	The metabolism of Pergolide can be decreased when combined with Verapamil.	Approved, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Verapamil.	Approved
Perindopril	The metabolism of Verapamil can be decreased when combined with Perindopril.	Approved
Permethrin	The metabolism of Permethrin can be decreased when combined with Verapamil.	Approved, Investigational
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Verapamil.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Verapamil.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Verapamil.	Withdrawn
Phenelzine	The risk or severity of adverse effects can be increased when Verapamil is combined with Phenelzine.	Approved
Phenobarbital	The metabolism of Verapamil can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Verapamil.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Verapamil.	Approved
Phentolamine	The risk or severity of adverse effects can be increased when Verapamil is combined with Phentolamine.	Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Verapamil.	Approved, Vet Approved
Phosphoramidon	The metabolism of Verapamil can be decreased when combined with Phosphoramidon.	Experimental
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Verapamil.	Approved
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Verapamil.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Verapamil.	Approved
Pindolol	The risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Verapamil.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Verapamil is combined with Pipamperone.	Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Verapamil.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Verapamil.	Approved
Platelet Activating Factor	The serum concentration of Verapamil can be decreased when it is combined with Platelet Activating Factor.	Experimental
Podofilox	The metabolism of Podofilox can be decreased when combined with Verapamil.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Verapamil.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Verapamil.	Approved
Poractant alfa	Verapamil may increase the bradycardic activities of Poractant alfa.	Approved
Posaconazole	The metabolism of Verapamil can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Practolol	Verapamil may increase the hypotensive activities of Practolol.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Verapamil is combined with Pramipexole.	Approved, Investigational
Prasterone	The metabolism of Prasterone can be decreased when combined with Verapamil.	Approved, Nutraceutical
Prasugrel	The metabolism of Prasugrel can be decreased when combined with Verapamil.	Approved
Pravastatin	The metabolism of Pravastatin can be decreased when combined with Verapamil.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Verapamil.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Verapamil.	Approved, Vet Approved
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Verapamil.	Approved
Prednisolone	The metabolism of Prednisolone can be decreased when combined with Verapamil.	Approved, Vet Approved
Prednisone	The metabolism of Prednisone can be decreased when combined with Verapamil.	Approved, Vet Approved
Primaquine	The metabolism of Primaquine can be decreased when combined with Verapamil.	Approved
Primidone	The metabolism of Verapamil can be increased when combined with Primidone.	Approved, Vet Approved
Prinomastat	The metabolism of Verapamil can be decreased when combined with Prinomastat.	Investigational
Probenecid	The serum concentration of Verapamil can be increased when it is combined with Probenecid.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Verapamil.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Verapamil.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Verapamil.	Approved
Promazine	The metabolism of Promazine can be decreased when combined with Verapamil.	Approved, Vet Approved
Promethazine	The serum concentration of Verapamil can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Propafenone can be increased when it is combined with Verapamil.	Approved
Propofol	The metabolism of Propofol can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.	Approved, Investigational
Protriptyline	The serum concentration of Verapamil can be increased when it is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Verapamil.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Verapamil.	Approved
Pyrimethamine	The metabolism of Verapamil can be decreased when combined with Pyrimethamine.	Approved, Vet Approved
Quazepam	The serum concentration of Verapamil can be increased when it is combined with Quazepam.	Approved, Illicit
Quercetin	The serum concentration of Verapamil can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Verapamil.	Approved
Quinapril	The metabolism of Verapamil can be decreased when combined with Quinapril.	Approved, Investigational
Quinidine	Quinidine may increase the hypotensive activities of Verapamil.	Approved
Quinine	The metabolism of Quinine can be decreased when combined with Verapamil.	Approved
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Verapamil.	Approved, Investigational
Radicicol	The risk or severity of adverse effects can be increased when Radicicol is combined with Verapamil.	Experimental
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Verapamil.	Approved, Investigational
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Verapamil.	Approved, Investigational
Ramipril	The metabolism of Verapamil can be decreased when combined with Ramipril.	Approved
Ranitidine	The serum concentration of Ranitidine can be decreased when it is combined with Verapamil.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Verapamil.	Approved, Investigational
Rapacuronium	Verapamil may increase the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Rasagiline	The risk or severity of adverse effects can be increased when Verapamil is combined with Rasagiline.	Approved
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Verapamil.	Approved, Investigational
Regorafenib	Regorafenib may increase the bradycardic activities of Verapamil.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Verapamil is combined with Remifentanil.	Approved
Remikiren	The metabolism of Verapamil can be decreased when combined with Remikiren.	Approved
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Verapamil.	Approved, Investigational
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.	Approved
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Verapamil.	Approved
Rifabutin	The metabolism of Verapamil can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Verapamil can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Verapamil can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Verapamil.	Approved, Investigational
Rilpivirine	The metabolism of Rilpivirine can be decreased when combined with Verapamil.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Verapamil.	Approved, Investigational
Riociguat	The risk or severity of adverse effects can be increased when Verapamil is combined with Riociguat.	Approved
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Verapamil.	Approved, Investigational
Ritonavir	The metabolism of Verapamil can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The metabolism of Verapamil can be decreased when combined with Rivaroxaban.	Approved
Rivastigmine	Verapamil may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Verapamil.	Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Verapamil.	Approved
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Verapamil.	Approved, Investigational
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Verapamil.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Verapamil.	Approved
Rosiglitazone	The metabolism of Verapamil can be decreased when combined with Rosiglitazone.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Verapamil.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Verapamil.	Approved
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Verapamil.	Approved, Withdrawn
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Verapamil.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Verapamil is combined with Sacubitril.	Approved
Salicylhydroxamic Acid	The risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Verapamil.	Experimental
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Verapamil.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Verapamil.	Approved
Saquinavir	The metabolism of Verapamil can be decreased when combined with Saquinavir.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Verapamil.	Approved
Scopolamine	The serum concentration of Verapamil can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Verapamil can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Verapamil.	Approved, Investigational, Vet Approved
Selexipag	The metabolism of Selexipag can be decreased when combined with Verapamil.	Approved
Sertaconazole	The risk or severity of adverse effects can be increased when Sertaconazole is combined with Verapamil.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Verapamil.	Approved, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Verapamil.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Verapamil.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Verapamil.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The metabolism of Verapamil can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Verapamil.	Approved
Siltuximab	The serum concentration of Verapamil can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Verapamil.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Verapamil.	Approved
Sinefungin	The risk or severity of adverse effects can be increased when Sinefungin is combined with Verapamil.	Experimental
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Verapamil.	Approved, Investigational
Sitagliptin	The metabolism of Verapamil can be decreased when combined with Sitagliptin.	Approved, Investigational
Sodium Nitrite	The risk or severity of adverse effects can be increased when Verapamil is combined with Sodium Nitrite.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Verapamil.	Approved
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Verapamil.	Approved
Solithromycin	The metabolism of Verapamil can be decreased when combined with Solithromycin.	Investigational
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Verapamil.	Approved, Investigational
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Verapamil.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Verapamil.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Verapamil.	Experimental
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Verapamil.	Approved
Spirapril	The metabolism of Verapamil can be decreased when combined with Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.	Approved
St. John's Wort	The serum concentration of Verapamil can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Verapamil can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Verapamil can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Verapamil is combined with Streptokinase.	Approved
Streptozocin	The serum concentration of Verapamil can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Verapamil.	Approved, Investigational
Sulconazole	The risk or severity of adverse effects can be increased when Sulconazole is combined with Verapamil.	Approved
Sulfadiazine	The metabolism of Verapamil can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.	Approved
Sulfisoxazole	The metabolism of Verapamil can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Verapamil can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Verapamil.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Verapamil.	Approved
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.	Approved
Tacrine	The serum concentration of Verapamil can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Verapamil.	Approved, Investigational
Tadalafil	The metabolism of Tadalafil can be decreased when combined with Verapamil.	Approved, Investigational
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Verapamil.	Approved
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Verapamil.	Approved, Investigational
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Verapamil.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Verapamil.	Experimental
Tavaborole	The risk or severity of adverse effects can be increased when Tavaborole is combined with Verapamil.	Approved
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Verapamil.	Approved
Telaprevir	The metabolism of Verapamil can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	Telithromycin may increase the bradycardic activities of Verapamil.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Verapamil.	Approved
Temocapril	The metabolism of Verapamil can be decreased when combined with Temocapril.	Experimental, Investigational
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Verapamil.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Verapamil.	Approved
Tenofovir disoproxil	The metabolism of Verapamil can be decreased when combined with Tenofovir.	Approved, Investigational
Terazosin	The risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.	Approved
Terbinafine	The risk or severity of adverse effects can be increased when Terbinafine is combined with Verapamil.	Approved, Investigational, Vet Approved
Terconazole	The risk or severity of adverse effects can be increased when Terconazole is combined with Verapamil.	Approved
Terfenadine	The metabolism of Terfenadine can be decreased when combined with Verapamil.	Withdrawn
Teriflunomide	The serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.	Approved
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Verapamil.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Verapamil.	Approved, Investigational
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Verapamil.	Approved, Vet Approved
Thalidomide	The risk or severity of adverse effects can be increased when Verapamil is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Verapamil.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Verapamil.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Verapamil.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Verapamil.	Withdrawn
Thiorphan	The metabolism of Verapamil can be decreased when combined with Thiorphan.	Experimental
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Verapamil.	Approved
Thymol	The risk or severity of adverse effects can be increased when Thymol is combined with Verapamil.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Verapamil.	Approved
Ticagrelor	The metabolism of Ticagrelor can be decreased when combined with Verapamil.	Approved
Ticlopidine	The metabolism of Verapamil can be decreased when combined with Ticlopidine.	Approved
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Verapamil.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Verapamil.	Approved, Investigational
Tioconazole	The risk or severity of adverse effects can be increased when Tioconazole is combined with Verapamil.	Approved
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Verapamil.	Approved
Tipranavir	The metabolism of Verapamil can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	The serum concentration of Tizanidine can be increased when it is combined with Verapamil.	Approved
Tocilizumab	The serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Verapamil.	Approved, Investigational
Tolazoline	The risk or severity of adverse effects can be increased when Verapamil is combined with Tolazoline.	Approved, Vet Approved
Tolbutamide	The metabolism of Verapamil can be decreased when combined with Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Verapamil is combined with Tolcapone.	Approved, Withdrawn
Tolnaftate	The risk or severity of adverse effects can be increased when Tolnaftate is combined with Verapamil.	Approved, Vet Approved
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Verapamil.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Verapamil.	Approved
Topiramate	The metabolism of Verapamil can be decreased when combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Verapamil.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.	Approved
Toremifene	The metabolism of Toremifene can be decreased when combined with Verapamil.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Verapamil.	Approved, Investigational
Tramadol	The metabolism of Tramadol can be decreased when combined with Verapamil.	Approved, Investigational
Trandolapril	The metabolism of Verapamil can be decreased when combined with Trandolapril.	Approved
Tranylcypromine	The metabolism of Verapamil can be decreased when combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The metabolism of Trastuzumab emtansine can be decreased when combined with Verapamil.	Approved
Trazodone	The metabolism of Trazodone can be decreased when combined with Verapamil.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Verapamil.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Verapamil.	Approved, Vet Approved
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.	Approved
Triazolam	The metabolism of Triazolam can be decreased when combined with Verapamil.	Approved
Trifluoperazine	The serum concentration of Verapamil can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Verapamil can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Verapamil.	Experimental
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Verapamil.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Verapamil.	Approved, Vet Approved
Trimetrexate	The risk or severity of adverse effects can be increased when Trimetrexate is combined with Verapamil.	Approved, Investigational
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Verapamil.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Verapamil.	Withdrawn
Ubenimex	The metabolism of Verapamil can be decreased when combined with Ubenimex.	Experimental
Udenafil	The metabolism of Udenafil can be decreased when combined with Verapamil.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Verapamil.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Verapamil.	Approved
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Verapamil.	Investigational, Withdrawn
Valproic Acid	The metabolism of Verapamil can be decreased when combined with Valproic Acid.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.	Approved, Investigational
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Verapamil.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Verapamil.	Investigational
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Verapamil.	Approved
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Verapamil.	Approved
Vemurafenib	The serum concentration of Verapamil can be increased when it is combined with Vemurafenib.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Verapamil.	Approved
Venlafaxine	The metabolism of Verapamil can be decreased when combined with Venlafaxine.	Approved
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Verapamil.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Verapamil.	Approved
Vildagliptin	The metabolism of Verapamil can be decreased when combined with Vildagliptin.	Approved, Investigational
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Verapamil.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Verapamil.	Approved, Investigational
Vincristine	The metabolism of Vincristine can be decreased when combined with Verapamil.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Verapamil.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Verapamil.	Approved, Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Verapamil.	Approved
Voriconazole	The metabolism of Verapamil can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Verapamil.	Approved
Warfarin	The metabolism of Warfarin can be decreased when combined with Verapamil.	Approved
Ximelagatran	The metabolism of Verapamil can be decreased when combined with Ximelagatran.	Approved, Investigational, Withdrawn
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Verapamil.	Approved, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Verapamil.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Verapamil.	Approved
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Verapamil.	Approved, Illicit, Investigational
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Verapamil.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Verapamil.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Verapamil can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Verapamil can be decreased when combined with Ziprasidone.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Verapamil.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Verapamil.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Verapamil.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Verapamil.	Approved
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.	Approved, Investigational

Food Interactions

Avoid alcohol.
Avoid excessive quantities of coffee or tea (Caffeine).
Avoid natural licorice.
Avoid taking with grapefruit juice.
Take with food.

References

Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, "Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms." U.S. Patent US4859469, issued April, 1987.

US4859469

General References

Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB01850
KEGG Drug	D02356
KEGG Compound	C07188
PubChem Compound	2520
PubChem Substance	46508158
ChemSpider	2425
BindingDB	81939
ChEBI	77733
ChEMBL	CHEMBL6966
Therapeutic Targets Database	DAP000040
PharmGKB	PA451868
IUPHAR	2406
Guide to Pharmacology	2406
Drug Product Database	10110
RxList	http://www.rxlist.com/cgi/generic/verapsr.htm
Drugs.com	http://www.drugs.com/verapamil.html
Wikipedia	Verapamil

ATC Codes

C08DA51 — Verapamil, combinations

C08DA01 — Verapamil

C09BB10 — Trandolapril and verapamil

AHFS Codes

24:28.92

PDB Entries

Not Available

FDA label

Download (1.9 MB)

MSDS

Download (73.5 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Crohn's Disease (CD)	1
1	Completed	Not Available	Drug Dependence	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Basic Science	Drug Drug Interactions / Healthy Volunteers	1
1	Completed	Basic Science	Drug-Drug Interaction (DDI) / Healthy Volunteers	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Basic Science	Healthy Volunteers / Pharmacokinetics of ASP015K	1
1	Completed	Basic Science	Pharmacokinetics	1
1	Completed	Diagnostic	Chronic Subjective Dizziness / Vestibular Migraine	1
1	Completed	Treatment	Drug-induced Surface ECG Changes	1
1	Completed	Treatment	Healthy Volunteers	4
1	Completed	Treatment	Stroke, Ischemic	1
1	Not Yet Recruiting	Treatment	Stroke, Ischemic	1
1	Recruiting	Basic Science	Cardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions	1
1	Recruiting	Other	Drug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics	1
1	Recruiting	Treatment	Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma	1
1	Withdrawn	Treatment	Stroke, Ischemic	1
1, 2	Completed	Health Services Research	Healthy Volunteers	1
1, 2	Recruiting	Treatment	Polyps, Nasal / Sinusitis	1
1, 2	Terminated	Treatment	Osteoarthritis of the Knees	1
2	Completed	Treatment	Brain Cancer / Cancers / Meningiomas	1
2	Completed	Treatment	Dravet Syndrome	1
2	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2, 3	Completed	Treatment	Cluster Headache	1
2, 3	Recruiting	Treatment	Ventricular Arrythmias	1
3	Completed	Treatment	Arrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation	1
3	Completed	Treatment	BMI >30 kg/m2 / Hypertensive	1
3	Completed	Treatment	Mania	1
3	Completed	Treatment	Nonvalvular Atrial Fibrillation	1
3	Terminated	Treatment	Heart Failure, Unspecified / Nonvalvular Atrial Fibrillation	1
4	Completed	Prevention	Renal Stones	1
4	Completed	Treatment	Acute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention (PCI)	1
4	Completed	Treatment	Diabetes / Hypertensive	1
4	Completed	Treatment	Diabetes / Hypertensive / Proteinuria	1
4	Completed	Treatment	Heart Disease, Ischemic	1
4	Completed	Treatment	Hypertensive	2
4	Completed	Treatment	Hypertensive / Metabolic Syndromes	1
4	Completed	Treatment	Marfan Syndrome	1
4	Completed	Treatment	Paroxysmal Supraventricular Tachycardia	1
4	Completed	Treatment	Rapid Ventricular Response Atrial Fibrillation	1
4	Enrolling by Invitation	Treatment	BMI >30 kg/m2 / General Surgery / Hypoglycemia	1
4	Recruiting	Health Services Research	Cerebral Vasospasm	1
4	Recruiting	Treatment	Reversible cerebral vasoconstriction syndrome	1
4	Terminated	Prevention	Keloid Scars	1
4	Unknown Status	Treatment	Congestive Cardiomyopathy	1
4	Unknown Status	Treatment	Heart Failure With Reduced Ejection Fraction (HFrEF) / Myocardial Diseases / Prophylaxis of cardiomyopathy	1
Not Available	Completed	Not Available	Coronary Heart Disease (CHD) / Verapamil Toxicity	1
Not Available	Completed	Not Available	Erectile Dysfunction (ED)	1
Not Available	Completed	Treatment	Arrythmias / Nonvalvular Atrial Fibrillation	1
Not Available	Completed	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Treatment	Nonvalvular Atrial Fibrillation	1
Not Available	Terminated	Treatment	Polyps, Nasal / Sinusitis	1
Not Available	Unknown Status	Treatment	Epilepsies / Seizures	1
Not Available	Withdrawn	Treatment	Catamenial Epilepsy	1

Pharmacoeconomics

Manufacturers

Mylan pharmaceuticals inc
Elan drug delivery inc
Gd searle llc
Fsc laboratories inc
Abraxis pharmaceutical products
Bedford laboratories div ben venue laboratories inc
Hospira inc
International medication system
Luitpold pharmaceuticals inc
Marsam pharmaceuticals llc
Smith and nephew solopak div smith and nephew
Solopak medical products inc
Ranbaxy laboratories inc
Glenmark generics ltd
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Par pharmaceutical inc
Pliva inc
Actavis elizabeth llc
Heritage pharmaceuticals inc
Mutual pharmaceutical co inc
Sandoz inc
Warner chilcott div warner lambert co
Watson laboratories inc

Packagers

Abbott Laboratories Ltd.
Advanced Pharmaceutical Services Inc.
Alza Corp.
Amerisource Health Services Corp.
Apotheca Inc.
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
BASF Corp.
Cardinal Health
Caremark LLC
Comprehensive Consultant Services Inc.
Copley Chemical Co.
Dee Stevens and Son Feeder
Dept Health Central Pharmacy
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Duramed
Elan Pharmaceuticals Inc.
FSC Laboratories
GD Searle LLC
General Injectables and Vaccines Inc.
Glenmark Generics Ltd.
Golden State Medical Supply Inc.
Group Health Cooperative
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Hospira Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Major Pharmaceuticals
Medisca Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmacia Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Prescript Pharmaceuticals
Ranbaxy Laboratories
Remedy Repack
Resource Optimization and Innovation LLC
Sandhills Packaging Inc.
Schwarz Pharma Inc.
Southwood Pharmaceuticals
Talbert Medical Management Corp.
Tya Pharmaceuticals
UDL Laboratories
United Research Laboratories Inc.
Vangard Labs Inc.
Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet, extended release	Oral	120 mg
Tablet, extended release	Oral	180 mg
Tablet	Oral	80 mg
Tablet, extended release	Oral	180 mg/1
Tablet, extended release	Oral	240 mg/1
Tablet	Oral	120 mg
Tablet, extended release	Oral	240 mg
Tablet, extended release	Oral
Tablet, film coated, extended release	Oral
Capsule, extended release	Oral	120 mg/1
Capsule, extended release	Oral	180 mg/1
Capsule, extended release	Oral	240 mg/1
Injection	Intravenous	2.5 mg/mL
Injection, solution	Intravenous	2.5 mg/mL
Tablet	Oral	120 mg/1
Tablet	Oral	240 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	80 mg/1
Tablet, extended release	Oral	120 mg/1
Tablet, extended release	Oral	240 mg/301
Tablet, film coated	Oral	120 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated	Oral	80 mg/1
Tablet, film coated, extended release	Oral	120 mg/1
Tablet, film coated, extended release	Oral	180 mg/1
Tablet, film coated, extended release	Oral	240 mg/1
Liquid	Intravenous	2.5 mg
Solution	Intravenous	2.5 mg
Capsule, delayed release pellets	Oral	120 mg/1
Capsule, delayed release pellets	Oral	180 mg/1
Capsule, delayed release pellets	Oral	240 mg/1
Capsule, delayed release pellets	Oral	360 mg/1
Capsule, extended release	Oral	120 mg
Capsule, extended release	Oral	180 mg
Capsule, extended release	Oral	240 mg
Capsule, extended release	Oral	100 mg/1
Capsule, extended release	Oral	200 mg/1
Capsule, extended release	Oral	300 mg/1

Prices

Unit description	Cost	Unit
Verelan 360 mg 24 Hour Capsule	6.82USD	capsule
Verelan 360 mg cap pellet	6.73USD	pellet
Verelan pm 300 mg cap pellet	5.87USD	pellet
Verelan 240 mg 24 Hour Capsule	4.76USD	capsule
Verelan 240 mg cap pellet	4.58USD	pellet
Verelan 180 mg 24 Hour Capsule	4.22USD	capsule
Verelan 180 mg cap pellet	4.06USD	pellet
Verelan pm 200 mg cap pellet	4.04USD	pellet
Verelan 120 mg cap pellet	3.87USD	pellet
Verapamil HCl CR 300 mg 24 Hour Capsule	3.82USD	capsule
Isoptin sr 240 mg tablet	3.32USD	tablet
Verapamil hcl powder	3.24USD	g
Calan SR 240 mg Controlled Release Tabs	3.15USD	tab
Isoptin SR 240 mg Controlled Release Tabs	3.14USD	tab
Verelan pm 100 mg cap pellet	3.13USD	pellet
Calan sr 240 mg caplet	3.09USD	caplet
Covera-HS 240 mg 24 Hour tablet	3.09USD	tablet
Covera-hs 240 mg tablet sa	2.97USD	tablet
Isoptin sr 180 mg tablet	2.9USD	tablet
Calan SR 180 mg Controlled Release Tabs	2.8USD	tab
Isoptin SR 180 mg Controlled Release Tabs	2.74USD	tab
Calan sr 180 mg caplet	2.7USD	caplet
Verapamil HCl CR 200 mg 24 Hour Capsule	2.62USD	capsule
Isoptin sr 120 mg tablet	2.29USD	tablet
Calan SR 120 mg Controlled Release Tabs	2.27USD	tab
Covera-HS 180 mg 24 Hour tablet	2.2USD	tablet
Isoptin SR 120 mg Controlled Release Tabs	2.16USD	tab
Calan sr 120 mg caplet	2.13USD	caplet
Covera-hs 180 mg tablet sa	2.11USD	tablet
Verapamil HCl CR 360 mg 24 Hour Capsule	2.1USD	capsule
Verapamil HCl CR 100 mg 24 Hour Capsule	2.04USD	capsule
Isoptin Sr 240 mg Sustained-Release Tablet	2.03USD	tablet
Calan sr 240 mg caplet sa	1.77USD	caplet
Verapamil HCl CR 240 mg 24 Hour Capsule	1.69USD	capsule
Verapamil HCl CR 240 mg Controlled Release Tabs	1.6USD	tab
Calan 120 mg tablet	1.56USD	tablet
Isoptin Sr 180 mg Sustained-Release Tablet	1.52USD	tablet
Verapamil HCl CR 180 mg 24 Hour Capsule	1.5USD	capsule
Calan sr 180 mg caplet sa	1.46USD	caplet
Verapamil HCl CR 120 mg 24 Hour Capsule	1.43USD	capsule
Verapamil HCl CR 180 mg Controlled Release Tabs	1.41USD	tab
Isoptin Sr 120 mg Sustained-Release Tablet	1.34USD	tablet
Calan 80 mg tablet	1.25USD	tablet
Verapamil 2.5 mg/ml vial	1.18USD	ml
Verapamil HCl CR 120 mg Controlled Release Tabs	1.12USD	tab
Apo-Verap Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet	0.91USD	tablet
Calan 40 mg tablet	0.76USD	tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet	0.72USD	tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet	0.72USD	tablet
Verapamil HCl 120 mg tablet	0.71USD	tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet	0.69USD	tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet	0.69USD	tablet
Verapamil HCl 80 mg tablet	0.56USD	tablet
Apo-Verap 120 mg Tablet	0.45USD	tablet
Mylan-Verapamil 120 mg Tablet	0.45USD	tablet
Nu-Verap 120 mg Tablet	0.45USD	tablet
Verapamil 120 mg tablet	0.39USD	tablet
Verapamil 80 mg tablet	0.31USD	tablet
Verapamil HCl 40 mg tablet	0.29USD	tablet
Apo-Verap 80 mg Tablet	0.29USD	tablet
Mylan-Verapamil 80 mg Tablet	0.29USD	tablet
Nu-Verap 80 mg Tablet	0.29USD	tablet
Verapamil 40 mg tablet	0.28USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5785994	No	1992-10-22	2009-10-22	US
US6096339	No	1997-04-04	2017-04-04	US

Properties

State

Liquid

Experimental Properties

Property	Value	Source
melting point (°C)	< 25 °C	PhysProp
boiling point (°C)	243-246 °C at 1.00E-02 mm Hg	PhysProp
water solubility	4.47 mg/L	Not Available
logP	3.79	HANSCH,C ET AL. (1995)
Caco2 permeability	-4.58	ADME Research, USCD
pKa	8.92	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.00394 mg/mL	ALOGPS
logP	5.23	ALOGPS
logP	5.04	ChemAxon
logS	-5.1	ALOGPS
pKa (Strongest Basic)	9.68	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	63.95 Å²	ChemAxon
Rotatable Bond Count	13	ChemAxon
Refractivity	132.65 m³·mol^-1	ChemAxon
Polarizability	51.7 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9371
Blood Brain Barrier	+	0.6323
Caco-2 permeable	+	0.738
P-glycoprotein substrate	Substrate	0.7874
P-glycoprotein inhibitor I	Inhibitor	0.9056
P-glycoprotein inhibitor II	Inhibitor	0.855
Renal organic cation transporter	Inhibitor	0.6259
CYP450 2C9 substrate	Non-substrate	0.8029
CYP450 2D6 substrate	Non-substrate	0.8706
CYP450 3A4 substrate	Substrate	0.7657
CYP450 1A2 substrate	Non-inhibitor	0.9553
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Inhibitor	0.796
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9181
Ames test	Non AMES toxic	0.8393
Carcinogenicity	Non-carcinogens	0.6463
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	3.4137 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7687
hERG inhibition (predictor II)	Inhibitor	0.8188

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)	splash10-004l-0702900000-6a46ea2d5eed6d8b01eb	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)	splash10-0006-4109800000-80d342090a0be3344e82	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)	splash10-054w-0954400000-2def387c7c93ab211423	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive	splash10-0a4i-0000900000-4cde9a4b3a4f83d16afc	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive	splash10-0a4i-0000900000-980b47834e505d54a0e6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive	splash10-066r-0902800000-ae024239c46b33917426	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive	splash10-014i-0901000000-81d1159b3102cff76218	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive	splash10-014i-0900000000-d9c344fee7b45b4030e6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	splash10-0gb9-0914000000-070bdb975910e9aae99c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	splash10-03di-0390000000-f41d80462c5d06c4f001	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	splash10-0097-2980000000-9a2ab0bcab33f7eaac6b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	splash10-0uxr-0900000000-252a9989a8511cb2db80	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive	splash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-0000900000-4365a47b2dc2f86bb272	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-0000900000-e6a2b357160bf5b92c22	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-066r-0902400000-d8eac2ccd0a767c7e432	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0901000000-688f3c2345c5d9ccb8a5	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0900000000-cd09f8a2be876936f662	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0uxr-0918000000-76641dd6dbc5cb05e79a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0a4i-0000900000-05ea95eb1f39b6515212	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-066r-0902600000-a675e624692c25472ce8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-014i-0901000000-70d820628d2613557239	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0gb9-0900000000-e3ca24cf75d574df08a8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0uyi-0900000000-f3a9fa002c56d3e5689a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , positive	splash10-0zg0-2900000000-101e077b890671063633	View in MoNA
MS	Mass Spectrum (Electron Ionization)	splash10-0udi-3519000000-b5e0b9e0caac5cb57222	View in MoNA
1D NMR	1H NMR Spectrum	Not Available
2D NMR	[1H,13C] 2D NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Phenylbutylamines

Direct Parent

Phenylbutylamines

Alternative Parents

Dimethoxybenzenes / Phenylpropanes / Phenethylamines / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Nitriles / Organopnictogen compounds

Substituents

Phenylbutylamine / Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Alkyl aryl ether

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

tertiary amino compound, aromatic ether, nitrile, polyether (CHEBI:77733 )

Get DrugBank to go!

Structure for DB00661 (Verapamil)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

References

References

References

References

References

References

Transporters

References

References

References

References

References

References

References

References

References

References

References

References

References